CD274 and non-small cell lung carcinoma: However, contrary to data from PD-(L)1 monotherapy in advanced NSCLC without preceding CRT exposure12 we found no significant difference in outcomes between tumors with PD-L1 TPS < 1% and 1–49% in our patient cohorts.